In the developed countries diabetic retinopathy is often not treated early enough, or is treated inadequately and sometimes not treated at all. Otherwise one could not explain why a complication for which effective treatment has been available now for over 10 years remains the most common cause of blindness in people between the ages of 30 and 64 years [1, 2] . The main problem is that patients with sight threatening lesions have to be identified; this is often difficult because the condition is asymptomatic at the stage when photocoagulation is most effective. In contrast, once vision is lost it is often difficult or impossible to restore it. Thus, we cannot wait for the patients to come to us, we have to plan prevention of blindness in diabetes mellitus through early detection of retinopathy, the obvious solution being screening. At present screening for diabetic retinopathy is haphazard, and not well organised. Screening programmes are expensive and time consuming, and health administrators in most countries have limited budgets which they find difficult to stretch to include the major work in organising preventive networks for eye care in diabetes.
The criteria for establishing screening services are: the condition must be an important health problem, affecting an identifiable population. An effective treatment must be available and, as well as a suitable screening test, acceptable to the population. The natural history of the condition must be understood, and an early pre-symptomatic stage must exist during which treatment is effective. Finally, the screening and treatment must be cost effective.
All these criteria are true for diabetic retinopathy. It has been shown to be an important health problem, and the population at risk, all diabetic patients, is easily identifiable. During the last 30 years the natural history of the condition has been clearly described, and in the 1970's and early 1980's randomised controlled clinical trials have amply proved the value of photocoagulation [3] [4] [5] [6] [7] . In an analysis of previous papers Rohan et al. [8] noted an average reduction of blindness by 73% (range 61 to 85 %). The long-term effectiveness of treatment has also been shown [9, 10] . Not only is blindness decreased, but the frequent occurrence of temporary visual loss due to recurrent vitreous haemorrhages is also reduced.
Is there a suitable screening test? Use of direct and indirect ophthalmoscopy through a dilated pupil will allow the identification of most patients who require treatment. Retinal photography using the non-mydriatic camera (though preferably with mydriasis), standard retinal photography preferably with stereo pictures of the macula, fluorescein angiography and slit lamp biomicroscopy all have their place in determining whom to treat, when to treat, and what to treat. When to use these methods and who should use them has long been a bone of contention. A recent workshop at the Hammersmith Hospital in London addressed these problems. The workshop was convened under the aegis of the European regions of the World Health Organisation (WHO) and the International Diabetes Federation, as a follow-up of the St. Vincent Declaration of 1989, which pledged to implement policies which will reduce the mortality and morbidity due to diabetes in Europe [11] . The workshop, at which ophthalmologists and diabetologists represented 2l European countries produced a consensus document on both screening and treatment [12] .
There was uniform agreement about the importance of screening programmes. These have to be staffed by adequately trained personnel, who have direct access to treatment facilities. The diabetic patients have to be identified and persuaded to avail themselves of these screening procedures. All this requires time, organisation and atso money. In order to convince the health authorities, with limited budgets that the investment in screening is cost effective we have to produce figures. Such figures are available from Scotland in 1983 [13] , and from the USA, in 1989 [14] . Both these studies indicate that the financial expenditure involved in identifying and treating one patient at risk of blindness is approximately 1/10 of the cost of maintaining this patient and his family on social benefit for the first year alone. This does not take into account the expenses of mobility training, teaching of Braille and re-training many of the sufferers. Nor does it take into account that blind patients and their families have to be supported for many years. Most important of all it does not take into account the improved quality of life maintaining vision confers.
The WHO will distribute the documents produced to the various European governments. The diabetologists and the ophthalmologists are already aware of the importance of screening. Thus, double pressure, from above and below, should force health authorities to support screening programmes. But organisation of these, implementation of the aims of the St.Vincent Declaration [11] to reduce the incidence of new blindness by one third in the next 5 years, remains in the hands of the doctors. Hopefully we are ready for this huge but important task. 
